TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07250724: C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

Sponsor: Bactolife A/S · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 60 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$793,800

Rescue Site Savings

+$529,200

Unlock Full NCT07250724 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07250724 Rescue Dossier →